ValuEngine Upgrades Xenon Pharmaceuticals (XENE) to Hold
Xenon Pharmaceuticals (NASDAQ:XENE) was upgraded by equities researchers at ValuEngine from a “sell” rating to a “hold” rating in a report released on Thursday.
Separately, Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday.
Shares of Xenon Pharmaceuticals (NASDAQ XENE) opened at $4.40 on Thursday. Xenon Pharmaceuticals has a fifty-two week low of $2.10 and a fifty-two week high of $9.95. The stock has a market cap of $67.49, a PE ratio of -2.77 and a beta of 1.08.
WARNING: “ValuEngine Upgrades Xenon Pharmaceuticals (XENE) to Hold” was first posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2018/03/03/valuengine-upgrades-xenon-pharmaceuticals-xene-to-hold.html.
Xenon Pharmaceuticals Company Profile
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.